Navidea Biopharmaceuticals (NAVB) Competitors $0.0001 0.00 (0.00%) (As of 12/20/2024 04:04 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainSEC FilingsTrends NAVB vs. VAXX, EVLO, SCPS, GNCAQ, GNCA, ARDS, STAB, AMPE, CMRA, and CALAShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Vaxxinity (VAXX), Evelo Biosciences (EVLO), Scopus BioPharma (SCPS), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Vaxxinity Evelo Biosciences Scopus BioPharma Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Comera Life Sciences Calithera Biosciences Vaxxinity (NASDAQ:VAXX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability. Do insiders and institutionals believe in VAXX or NAVB? 82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor VAXX or NAVB? Vaxxinity received 5 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 38.46% of users gave Vaxxinity an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformVaxxinityOutperform Votes538.46% Underperform Votes861.54% Navidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes68100.00% Is VAXX or NAVB more profitable? Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Does the media prefer VAXX or NAVB? In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Vaxxinity Neutral Navidea Biopharmaceuticals Neutral Which has more risk and volatility, VAXX or NAVB? Vaxxinity has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Which has stronger earnings and valuation, VAXX or NAVB? Navidea Biopharmaceuticals has lower revenue, but higher earnings than Vaxxinity. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinity$70K0.54-$56.93M-$0.450.00Navidea Biopharmaceuticals$8.13K1.23-$15.18M-$0.060.00 SummaryVaxxinity beats Navidea Biopharmaceuticals on 6 of the 10 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$10,000.00$2.51B$5.14B$19.19BDividend YieldN/A0.73%5.09%3.62%P/E Ratio0.006.0790.1341.30Price / Sales1.2375.121,117.0917.51Price / CashN/A15.0543.1021.28Price / Book0.003.284.785.32Net Income-$15.18M$29.98M$120.31M$989.88M7 Day PerformanceN/A-1.55%-1.92%-3.54%1 Month PerformanceN/A6.18%13.65%-4.73%1 Year PerformanceN/A-20.93%28.34%11.57% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-99.8%$10,000.00$8,126.000.0010Analyst ForecastVAXXVaxxinityN/A$0.00+100.0%N/A-100.0%$25,000.00$70,000.000.0090EVLOEvelo BiosciencesN/A$0.00+25.0%N/A-99.1%$9,000.00N/A0.00120SCPSScopus BioPharmaN/A$0.00-33.3%N/A-99.3%$8,000.00N/A0.009Gap UpGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.64M0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5,000.00$3.09M0.0030News CoverageSTABStatera BiopharmaN/A$0.00flatN/A-75.0%$5,000.00$1.49M0.0020AMPEAmpio PharmaceuticalsN/A$0.00+420.0%N/A-99.9%$3,000.00N/A0.0020Analyst ForecastCMRAComera Life SciencesN/A$0.00flatN/AN/A$3,000.00$630,000.000.002CALACalithera BiosciencesN/A$0.00-92.1%N/A-99.7%$1,000.00$9.75M0.0060Analyst ForecastGap Down Related Companies and Tools Related Companies Vaxxinity Competitors Evelo Biosciences Competitors Scopus BioPharma Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors Comera Life Sciences Competitors Calithera Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NAVB) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAVB Stock Alerts